â ???? Immuron Ltd ADR (NASDAQ:


) Â Shares rose over 43% on Wednesday as it was announced the Department of Defense received A $ 6.2 million ($ 4.45 million) for clinical evaluation of a dosage regimen for Travelan’s military strength.

Immuron received A $ 4.8 million ($ 3.43 million) funding from the Department of Defense for Travelan, while the U.S. Naval Medical Research Center received A $ 1.4 million ($ 1.02 million) in clinical support Development received a million.

Travelan is a diarrhea drug whose funds are being made available to test the effectiveness of a single higher dose in diarrhea caused by enterotoxigenic Escherichia coli

It is planned to have a clinical To conduct a human controlled infection model study in 60 healthy volunteers in the United States.

“This new project expands our clinical development program and represents the first of represent several significant clinical studies that the company expects to conduct with the US military in 2022, ”said Dr. Jerry Kanellos, CEO of Immuron.

We encourage you to use comments to connect with users, share your perspective, and ask questions to authors and each other. However, to maintain the high level of discourse that we all value and expect, please note the following criteria:

Spam or abusive offenders will be removed from the website and excluded from future registration at’s discretion.

Insert a picture here or
Upload from your computer
Supported formats: * .jpg, * .png, * .gif up to 5 MB

Risk Warning: Fusion Media assumes no liability for any loss or damage that may arise from reliance on the information contained on this website, including data, prices, charts and buy / sell signals. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Forex trading on margin carries a high level of risk and is not suitable for all investors. Trading or investing in cryptocurrencies carries potential risks. The prices of cryptocurrencies are extremely volatile and can be influenced by external factors such as financial, regulatory or political events. Cryptocurrencies are not suitable for all investors. Before deciding to trade forex or other financial instruments or cryptocurrencies, you should carefully consider your investment goals, level of experience and risk tolerance. Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) as well as forex and cryptocurrency prices are not provided by exchanges, but by market makers. Therefore, prices may not be accurate and may differ from the actual market price, meaning that prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may incur as a result of using this data. Fusion Media may be compensated by the advertisers appearing on the site based on your interaction with the advertisements or advertisers